EGRX up +8.73% percent right now. $EGRX High is at

EGRX up +8.73% percent right now. $EGRX High is at 13.85 and the Low 12.16 with current volume of 102,357.

Recent News posted below.

EGRX Eagle Pharmaceuticals Inc. Recent Headline News

Eagle Pharma rapidly infused admix equivalent to Treanda
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:51AM CST

EGRX: 13.49 (+1.01)

Eagle Pharmaceuticals Reports Positive Outcomes from Clinical Trial of Bendamustine HCl Product Delivered via Low-Volume, Rapidly Infused Admixture
Business Wire - Mon Nov 10, 6:33AM CST
--Safety Profile of Eagle's Product is Comparable to Treanda
EGRX: 13.49 (+1.01)

Eagle Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
Business Wire - Fri Nov 07, 8:40AM CST
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company" announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the Stifel 2014 Healthcare Conference as follows:
EGRX: 13.49 (+1.01)

Global B-Cell Non-Hodgkin Lymphoma Therapeutics Pipeline Review H2 2014 - 43 Drug Profiles from 28 Leading Pharma Companies
M2 - Thu Oct 23, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72dlvw/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - Sanofi - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Biocon Limited - Ono Pharmaceutical Co., Ltd. - Sandoz Inc. - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Takara Bio Inc. - Simcere Pharmaceutical Group - Spectrum Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - LFB S.A. - Eagle Pharmaceuticals Inc. - Areta International s.r.l. - Molecular Templates Inc. - Aprogen, Inc. - BioMedics Japan Inc. For more information visit http://www.researchandmarkets.com/research/72dlvw/bcell
IMMU: 3.66 (+0.05), PTLA: 27.49 (+0.10), PCYC: 133.52 (+0.03), INCY: 70.01 (+0.69), AMGN: 162.34 (+2.09), SPPI: 7.42 (+0.09), BMY: 58.54 (+0.22), EGRX: 13.49 (+1.01), SGEN: 35.84 (-0.21), MRK: 58.87 (-0.47), CELGZ: 3.17 (-0.07)

Chimerix, Inc. (CMRX) in Focus: Stock Up 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 7:44AM CDT
Chimerix, Inc. (CMRX) was a big mover last session, as the company saw its shares rise nearly 6% on the day
ICUI: 70.94 (-0.22), CMRX: 31.04 (+0.29), ABAX: 52.34 (+0.71), EGRX: 13.49 (+1.01)

Strength Seen in CareFusion (CFN): Stock Soars 22.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 8:25AM CDT
CareFusion (CFN) was a big mover last session, with shares surging nearly 23% on the day.
ICUI: 70.94 (-0.22), ABAX: 52.34 (+0.71), CFN: 57.39 (+0.11), EGRX: 13.49 (+1.01)

Rockwell Medical (RMTI) Jumps: Stock Gains 15.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:25AM CDT
Rockwell Medical (RMTI) was a big mover last session, with shares rising nearly 16% on the day.
ICUI: 70.94 (-0.22), ABAX: 52.34 (+0.71), EGRX: 13.49 (+1.01), RMTI: 10.68 (+0.13)

Neogen Beats Q1 Earnings by a Penny; Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:10AM CDT
Following the announcement of the first quarter results, Neogen Corp. (NEOG) witnessed two upward estimate revisions over the last seven days for fiscal 2015, with no downward revision over the same time frame.
ICUI: 70.94 (-0.22), CNAT: 6.99 (+0.14), NEOG: 43.81 (+0.80), EGRX: 13.49 (+1.01)

Agios Pharmaceuticals (AGIO) Gains: Stock Up 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 7:44AM CDT
Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise 6.4% on the day.
ICUI: 70.94 (-0.22), SMA: 9.29 (+0.02), AGIO: 79.93 (+7.87), EGRX: 13.49 (+1.01)

Mead Johnson Unveils Production-R&D Center in Singapore - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 2:30PM CDT
The investment reflects Mead Johnson's (MJN) acknowledgement of the double-digit growth in its product demand in the Asian market over the past decade.
ICUI: 70.94 (-0.22), MJN: 99.19 (+0.80), CNAT: 6.99 (+0.14), EGRX: 13.49 (+1.01)

Owens & Minor to Acquire ArcRoyal in Ireland; Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 12:30PM CDT
Ever since Owens & Minor Inc. (OMI) entered the agreement to acquire ArcRoyal on Sep 19 this year, its shares have declined nearly 3.8% till yesterday.
ICUI: 70.94 (-0.22), CNAT: 6.99 (+0.14), EGRX: 13.49 (+1.01), OMI: 33.76 (-0.19)

Boston Scientific Initiates REPRISE III Clinical Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 2:20PM CDT
Boston Scientific (BSX) is well positioned to acquire a potentially larger share in the TAVR market in Europe.
BSX: 13.44 (+0.20), ICUI: 70.94 (-0.22), CNAT: 6.99 (+0.14), EGRX: 13.49 (+1.01)

Eagle Pharmaceuticals to Present at 21st Annual NewsMakers in the Biotechnology Industry Investment Conference
Business Wire - Tue Sep 23, 9:41AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, President and Chief Executive Officer, will present at the 21st Annual BioCentury NewsMakers Conference as follows:
EGRX: 13.49 (+1.01)

Covidien Sonicision Line Expands, 3 Devices Gain FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:20PM CDT
The newly-approved device lengths allow surgeons to expand their use of Covidien plc's (COV) Sonicision system to a more diverse range of surgical procedures.
ICUI: 70.94 (-0.22), ABAX: 52.34 (+0.71), COV: 92.60 (+0.52), EGRX: 13.49 (+1.01)

TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:46AM CDT
TG Therapeutics (TGTX) was a big mover last session, with shares rising over 16% on the day.
ICUI: 70.94 (-0.22), ABAX: 52.34 (+0.71), TGTX: 12.25 (+0.98), EGRX: 13.49 (+1.01)

St. Jude Medical Comes Up with Positive CardioMEMS Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:50PM CDT
The latest CHAMPION trial results demonstrated that monitoring the pulmonary artery pressure with St. Jude Medical Inc.'s (STJ) CardioMEMS HF System can reduce hospitalizations without adversely affecting renal function.
ICUI: 70.94 (-0.22), ABAX: 52.34 (+0.71), STJ: 65.57 (+0.81), EGRX: 13.49 (+1.01)

Eagle Pharmaceuticals Announces That Teva Requests a Motion to Dismiss with Prejudice in Its Bendamustine Patent Infringement Lawsuit
Business Wire - Wed Sep 17, 7:04AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Cephalon, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., has moved to dismiss with prejudice its first lawsuit alleging that Eagle's tentatively approved bendamustine hydrochloride injection infusion product infringes one of its patents, U.S. Patent No. 8,445,524. The case was filed in the United States District Court for the District of Delaware in October, 2013.
TEVA: 58.18 (+0.48), EGRX: 13.49 (+1.01)

Covidien's Two Neurovascular Trial Enrolments on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 12:30PM CDT
The PREMIER Prospective study is designed to evaluate Covidien plc's (COV) Pipeline embolization device while the STRATIS Registry for Endovascular Stroke Devices is meant for the company's market-released stroke devices.
ICUI: 70.94 (-0.22), ABAX: 52.34 (+0.71), COV: 92.60 (+0.52), EGRX: 13.49 (+1.01)

St. Jude Medical Reports Positive 12-Month EnligHTN Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 12:40PM CDT
The 12-month EnligHTN III data continues to show the benefits associated with St. Jude Medical Inc.'s (STJ) EnligHTN Renal Denervation System and merits for its potential to change the way hypertension is treated.
ICUI: 70.94 (-0.22), ABAX: 52.34 (+0.71), STJ: 65.57 (+0.81), EGRX: 13.49 (+1.01)

Strength Seen in Cardica (CRDC): Stock Adds 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 8:25AM CDT
Cardica (CRDC) was a big mover last session, with shares rising nearly 8% on the day.
ICUI: 70.94 (-0.22), ABAX: 52.34 (+0.71), CRDC: 0.91 (-0.05), EGRX: 13.49 (+1.01)